Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NAVBNASDAQ:NMTRNASDAQ:TCBPNASDAQ:TRVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAVBNavidea Biopharmaceuticals$0.01+1,566.7%$0.00$0.00▼$0.13$1.00M2.2110,452 shs703 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs4 shsTCBPTC Biopharm$0.68-55.8%$0.86$0.50▼$199.89$279K0.01138,842 shs5.33 million shsTRVNTrevena$1.20-0.8%$1.25$0.95▼$10.99$1.04M0.872,232 shs2,359 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAVBNavidea Biopharmaceuticals0.00%+1,566.67%+1,566.67%+1,328.57%-71.43%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%TCBPTC Biopharm0.00%0.00%0.00%-72.32%-99.63%TRVNTrevena-0.83%+11.11%+8.11%-33.70%-88.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATCBPTC Biopharm1.2087 of 5 stars3.50.00.00.00.00.80.6TRVNTrevenaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/ATCBPTC Biopharm 3.00Buy$48.006,948.46% UpsideTRVNTrevena 2.00Hold$5.00316.67% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNAVBNavidea Biopharmaceuticals$8.13K123.17N/AN/AN/A∞NMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ATCBPTC Biopharm$4.76M0.06N/AN/A$519.58 per share0.00TRVNTrevena$443K2.34N/AN/A($11.07) per share-0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ANMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ATCBPTC Biopharm-$7.35MN/A0.00∞N/AN/AN/AN/AN/ATRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ATCBPTC BiopharmN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNAVBNavidea BiopharmaceuticalsN/AN/AN/ANMTR9 Meters BiopharmaN/A0.590.59TCBPTC Biopharm0.671.12N/ATRVNTrevenaN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNAVBNavidea Biopharmaceuticals0.01%NMTR9 Meters Biopharma22.34%TCBPTC Biopharm16.25%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipNAVBNavidea Biopharmaceuticals43.68%NMTR9 Meters Biopharma2.40%TCBPTC Biopharm15.44%TRVNTrevena2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataTCBPTC Biopharm80410,00028,000Not OptionableTRVNTrevena40864,000841,000OptionableTCBP, NMTR, TRVN, and NAVB HeadlinesRecent News About These CompaniesBerks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball winApril 11, 2025 | readingeagle.comVanessa Hudgens and Oliver Trevena Appear at Expo West for CaliwaterMarch 9, 2025 | msn.comJMP Securities downgrades Trevena (TRVN) to a HoldDecember 28, 2024 | markets.businessinsider.com‘Plane’ Actor Oliver Trevena Signs With Untitled EntertainmentDecember 16, 2024 | yahoo.comLyme Regis town councillor John Trevena stand downDecember 11, 2024 | bridportnews.co.ukTrevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowDecember 10, 2024 | zacks.comTrevena appoints new financial chiefNovember 29, 2024 | investing.comTrevena Appoints Katrine Sutton as New CFONovember 27, 2024 | tipranks.comHC Wainwright & Co. Downgrades Trevena (TRVN)November 16, 2024 | msn.comTrevena, Inc. Navigates Financial Challenges and Strategic ChangesNovember 9, 2024 | msn.comChester County biopharm firm's latest layoffs impact its C-suiteNovember 7, 2024 | bizjournals.comTrevena teeters in dangerous territory, terminating CEO and other execs amid strategic reviewNovember 7, 2024 | fiercebiotech.comTrevena Reports Third Quarter 2024 Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comWhy Trevena (TRVN) Stock Is Down 43% TodayOctober 8, 2024 | msn.comTrevena, Inc. Faces Delisting from NasdaqOctober 6, 2024 | msn.comTrevena Announces Receipt of Nasdaq Delisting NotificationOctober 4, 2024 | globenewswire.comLearn to Evaluate (TRVN) using the ChartsSeptember 16, 2024 | news.stocktradersdaily.comTrevena (NASDAQ:TRVN) Stock Quotes, Forecast and News SummarySeptember 12, 2024 | benzinga.comTrevena Inc (TRVN) Stock: Surpassing Expectations in the Market?September 11, 2024 | bovnews.comTrevena Share Price (TRVN.US)August 19, 2024 | lse.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCBP, NMTR, TRVN, and NAVB Company DescriptionsNavidea Biopharmaceuticals NYSE:NAVB$0.01 +0.01 (+1,566.67%) As of 05/12/2025 02:19 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.TC Biopharm NASDAQ:TCBP$0.68 -0.86 (-55.78%) Closing price 03/21/2025Extended Trading$0.68 0.00 (0.00%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Trevena NASDAQ:TRVN$1.20 -0.01 (-0.83%) As of 05/14/2025 12:57 PM EasternTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
